

A global health industry leader



www.globalgreencross.com

GC Pharma(Former Green Cross Corp.)

GC Pharma has been a leading biotech company for developing innovative biotherapies including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies.

GC Pharma developed the world's first vaccine against epidemic hemorrhagic fever "Hantavax" and the world's second vaccine for varicella zoster virus vaccine "Suduvax".

GC Pharma is also pursuing opportunities in rare diseases by developing therapies such as Hunterase (world's second ERT for Hunter syndrome). In 2019, GC Pharma's total revenue rose to KRW 1.369 trillion.

Main Products

Product Name / Active Substance	Pharmacological Effects	Exporting Countries	Remarks
1) I.VGlobulin SN inj. / Human Intravenous Immunoglobulin	A-/Hypogammaglobulinemia Combined therapy with antibiotics for severe bacterial or viral infections Idiopathic thrombocytopenic purpura Guillain-Barre syndrome Kawasaki syndrome	Asia, Middle-East, Central & South America	Plasma Derivatives
2) Albumin injGCC / Human Albumin Solution	For hypoalbuminemia and shock in acute hemorrhage from loss of albumin (burns, nephrotic syndrome, etc.) and low synthesis of albumin (hepatic cirrhosis, etc.)	Asia, Middle-East, Central & South America	Plasma Derivatives
3) Green-VIII inj. / Human Blood Coagulation Factor VIII	For the treatment of hemophilia A with supplies of blood coagulation factor VIII	Asia, Middle-East, Central & South America	Plasma Derivatives
4) GreenGene F inj. / Recombinant Coagulation Factor VIII	episodes and preoperative management in hemophilia A	Asia, Middle-East, Central & South America	Recombinant Product
5) Hepabig inj. / Human Hepatitis B Immunoglobulin	For prophylaxis of hepatitis B after exposure to HBsAg For prophylaxis of hepatitis B in neonates	Asia, Middle-East, Central & South America	Plasma Derivatives
6) I.V. Hepabig inj. / Human Hepatitis B Immunoglobulin	For prevention of recurrence of hepatitis B in patients with liver transplants	Asia, Middle-East, Central & South America	Plasma Derivatives
7) Sero-Tet inj. / Human Tetanus Immunoglobulin	For the prophylaxis of tetanus and the reduction of tetanus symptoms	Asia, Middle-East, Central & South America	Plasma Derivatives
8) GCFLU PFS inj. / Split Virion, Trivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
9) GCFLU Quadrivalent PFS inj. / Split Virion, Quadrivalent Inactivated Influenza Vaccine	For the prophylaxis against influenza	Asia, Middle-East, Central & South America	Vaccines
10) Varicella vaccine-GCC inj. / Live Attenuated Varicella Vaccine	For the prophylaxis against varicella	Asia, Middle-East, Central & South America	Vaccines
11) Hunterase / Idursulfase beta	For treatment (Enzyme Replacement Therapy) of Hunter Syndrome (Mucopolysaccharidosis II)	Asia, Middle-East, Central & South America	Recombinant Product
12) Neulapeg PFS Inj. / PEG-GCSF	For decrease the duration of severe neutropenia for patients receiving cytotoxic chemotherapy for solid tumor and malignant lymphoma	Asia, Middle-East, Central & South America	Recombinant Product

R&D Pipeline

Pre-Clinical	Phase I	Phase II	Phase III	Registration /Pricing	
Factor X factor X deficiency	VZV (subunit) Vaccination for Varicella zoster virus	Anthrax Vaccination for Anthrax	IVIG-10% (US) Immune deficiency	SUDU II Vaccination for Varicella zoster virus	
PCC Bleeding disorder treatment	TFPI Hemophilia A/B treatment	Tdap Vaccination for Tetanus, Diphtheria, Pertussis	BCG Vaccination for BCG	GreenGene F (CN) Hemophilia A treatment	
vWF Bleeding disorder treatment		Hepabig-gene (CHB) Hepatitis B treatment	Hepabig-gene (LT) Hepatitis B prevention	Hunterase (CN) Hunter syndrome treatment	
RSV Vaccination for Respiratory syncytial virus		EGFR Cancer therapy	Hunterase (P3) Hunter syndrome treatment	Hunterase (ICV,JP) Hunter syndrome treatment	
CEACAM1 Cancer Immunotherapy			* Plasma Va	accine Recombinant	

CEO Eun-Chul Huh

Location

107, Ihyeon-ro 3obeon–gil, Giheung-gu, Yongin-si, Gyeonggi-do 16924, Korea

Specialty

- 1. Plasma Derivatives
- 2. Vaccine
- 3. Recombinant protein

Tel / Fax / E-mail

- T. 82-31-260-9300
- F. 82-31-260-9491